MedTrace Logo

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

NCT05175430 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-03-13

No results posted yet for this study

Summary

Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression and anxiety. SSRIs like paroxetine are first-line treatments for depression and anxiety disorders. Paroxetine acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.

Conditions

  • Healthy

Interventions

DRUG

Paroxetine

Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.

DRUG

Lysergic Acid Diethylamide

LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.

DRUG

Placebo

Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, Dr., MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2024-02-20
Completion
2024-03-07

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05175430 on ClinicalTrials.gov